Europska Unija - hrvatski - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cjepiva - active immunisation against h5 subtype of influenza a virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a - živjeti ets - tk - dual-gen-uklonjen goveđi herpes virus tip 1, soj ceddel: 106.3–107.3 ccid50 - immunologicals - stoka - za aktivna imunizacija goveda s tri mjeseca starosti goveda protiv virusa herpesa tipa 1 (bohv-1) za smanjenje kliničkih znakova infekcije ринотрахеита goveda (ИБР) i polje virus izlučivanje. početak imuniteta: 21 dan nakon završetka osnovne sheme cijepljenja. trajanje imuniteta: 6 mjeseci nakon završetka osnovne sheme cijepljenja .

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - svinje - za aktivnu imunizaciju svinja od sedam tjedana pa nadalje kako bi se spriječila smrtnost i smanjila infekcija i bolesti uzrokovane virusom klasične svinjske kuge (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Europska Unija - hrvatski - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - piletina - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - рекомбинантный virus везикулярного стоматита (soj indiana) s brisanje koverti glikoprotein, zamijenjen zair ebole (soj киквите 1995) površinski glikoprotein - Геморрагическая groznice ebole - cjepiva - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. korištenje ervebo moraju biti u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunološki za aves - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - imunomodulatori za псовые - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Europska Unija - hrvatski - EMA (European Medicines Agency)

virbac s.a. - živi atenuirani virus bjesnoće, sag2 soj - Živa virusna cjepiva - raccoon dogs (nyctereutes procyonoides); red foxes (vulpes vulpes) - za aktivnu imunizaciju crvenih lisica i rakovskih pasa kako bi se spriječila infekcija virusom bjesnoće. trajanje zaštite je najmanje 6 mjeseci.